Cargando…

Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials

BACKGROUND: Screening to identify individuals with elevated brain amyloid (Aβ+) for clinical trials in Preclinical Alzheimer’s Disease (PAD), such as the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s disease (A4) trial, is slow and costly. The Trial-Ready Cohort in Preclinical/Prodromal Alzheim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Langford, O., Raman, R., Sperling, R.A., Cummings, J., Sun, C.-K., Jimenez-Maggiora, G., Aisen, P.S., Donohue, M.C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745538/ https://www.ncbi.nlm.nih.gov/pubmed/32920622 http://dx.doi.org/10.14283/jpad.2020.44

Ejemplares similares

TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology
por: Jimenez-Maggiora, G.A., et al.
Publicado: (2020)

The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview
por: Aisen, P.S., et al.
Publicado: (2020)

Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD)
por: Walter, S., et al.
Publicado: (2020)

The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years
por: Walter, S., et al.
Publicado: (2020)

Predicting amyloid risk by machine learning algorithms based on the A4 screen data: Application to the Japanese Trial‐Ready Cohort study
por: Sato, Kenichiro, et al.
Publicado: (2021)

The Computerized Cognitive Composite (C3) in A4, an Alzheimer’s Disease Secondary Prevention Trial
por: Papp, K.V., et al.
Publicado: (2021)

Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
por: Raman, Rema, et al.
Publicado: (2021)

Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention
por: Insel, Philip S, et al.
Publicado: (2020)

Centralizing prescreening data collection to inform data-driven approaches to clinical trial recruitment
por: Kirn, Dylan R., et al.
Publicado: (2023)

Instrumental activities of daily living, amyloid, and cognition in cognitively normal older adults screening for the A4 Study
por: Marshall, Gad A., et al.
Publicado: (2020)

Early-stage Alzheimer disease: getting trial-ready
por: Aisen, Paul S., et al.
Publicado: (2022)

Brain amyloid burden, sleep, and 24-hour rest/activity rhythms: screening findings from the Anti-Amyloid Treatment in Asymptomatic Alzheimer’s and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration Studies
por: Spira, Adam P, et al.
Publicado: (2021)

Feasibility study for detection of retinal amyloid in clinical trials: The Anti‐Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial
por: Ngolab, Jennifer, et al.
Publicado: (2021)

The A4 study: β‐amyloid and cognition in 4432 cognitively unimpaired adults
por: Insel, Philip S., et al.
Publicado: (2020)

Item-Level Investigation of Participant and Study Partner Report on the Cognitive Function Index from the A4 Study Screening Data
por: Amariglio, R.E., et al.
Publicado: (2021)

The AHEAD 3–45 Study: Design of a prevention trial for Alzheimer’s disease
por: Rafii, Michael S., et al.
Publicado: (2023)

The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program
por: Berkness, Tyler, et al.
Publicado: (2021)

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Cross-validation of optimized composites for preclinical Alzheimer's disease
por: Donohue, Michael C., et al.
Publicado: (2016)

Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report
por: Gauthier, Serge, et al.
Publicado: (2020)

Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials
por: Grill, Joshua D, et al.
Publicado: (2015)

Corrigendum to: ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trials
por: Jimenez-Maggiora, Gustavo A, et al.
Publicado: (2022)

Alzheimer’s Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer’s Clinical Trial Consortium Sites
por: Rhodus, Elizabeth K., et al.
Publicado: (2022)

Impact of sex and APOE ε4 on the association of cognition and hippocampal volume in clinically normal, amyloid positive adults
por: Petersen, Kellen K., et al.
Publicado: (2022)

Plasma amyloid-β42/40 and apolipoprotein E for amyloid PET pre-screening in secondary prevention trials of Alzheimer’s disease
por: Cullen, Nicholas C, et al.
Publicado: (2023)

The Alzheimer's Disease Cooperative Study Prevention Instrument Project: Longitudinal Outcome of Behavioral Measures as Predictors of Cognitive Decline
por: Banks, Sarah Jane, et al.
Publicado: (2014)

Amyloid burden, cortical thickness, and cognitive function in the Wisconsin Registry for Alzheimer's Prevention
por: Doherty, Benjamin M., et al.
Publicado: (2015)

ATRI EDC: a novel cloud-native remote data capture system for large multicenter Alzheimer’s disease and Alzheimer’s disease-related dementias clinical trails
por: Jimenez-Maggiora, Gustavo A, et al.
Publicado: (2022)

Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden
por: Drzezga, Alexander, et al.
Publicado: (2011)

Associations of Stages of Objective Memory Impairment With Amyloid PET and Structural MRI: The A4 Study
por: Grober, Ellen, et al.
Publicado: (2022)

Longitudinal degradation of the default/salience network axis in symptomatic individuals with elevated amyloid burden.
por: Schultz, Aaron P, et al.
Publicado: (2019)

Tackling a Major Deficiency of Diversity in Alzheimer’s Disease Therapeutic Trials: An CTAD Task Force Report
por: Raman, Rema, et al.
Publicado: (2022)

The Amyloid-β Pathway in Alzheimer’s Disease
por: Hampel, Harald, et al.
Publicado: (2021)

Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease
por: Assunção, Sheila Seleri, et al.
Publicado: (2022)

Accelerated hypometabolism with disease progression associated with faster cognitive decline among amyloid positive patients
por: Yang, Zhengshi, et al.
Publicado: (2023)

Intranasal Insulin Reduces White Matter Hyperintensity Progression in Association with Improvements in Cognition and CSF Biomarker Profiles in Mild Cognitive Impairment and Alzheimer’s Disease
por: Kellar, D., et al.
Publicado: (2021)

Accelerated Amyloid Beta Pathogenesis by Bacterial Amyloid FapC
por: Javed, Ibrahim, et al.
Publicado: (2020)

Reduced vascular amyloid burden at microhemorrhage sites in cerebral amyloid angiopathy
por: van Veluw, Susanne J., et al.
Publicado: (2016)

Food protein-derived amyloids do not accelerate amyloid β aggregation
por: Rahman, M. Mahafuzur, et al.
Publicado: (2023)

The relative efficiency of time-to-progression and continuous measures of cognition in presymptomatic Alzheimer's disease
por: Li, Dan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6f80e8r2u0ue8ughi49v7dmked